CliffBio
small molecule

GLUCAGON

GLUCAGON

Loss of exclusivityApril 2026FDA regulatory exclusivity expiry
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameGLUCAGON
Active ingredientGLUCAGON
Strength1MG/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalSeptember 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTApril 2026

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

GLUCAGON patent cliff — loss of exclusivity April 2026 | CliffBio